Following a residency at Mt. Sinai Hospital in New York City, Dr Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr Dorff serves as an associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology. She has lectured on prostate and bladder cancer treatment nationally and internationally and has presented her research at national meetings. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and immunotherapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.
AstraZeneca, Astellas, Exelixis, Janssen and SeaGen.
Episode 3: Overview of efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented and the impact for the treatment of patients with mCRPC
On-demand e-learning, video replay and slide set now available
In this podcast Assoc. Prof. Tanya Dorff and Dr Neal Shore focus on patients with metastatic castration-sensitive prostate cancer (mCSPC) and discuss when to use androgen receptor signalling inhibitors (ARSI) and taxanes for these patients.
On-demand educational resources (e-learning, video and slide set) are now available following a successful GU CONNECT Experts Knowledge Share event on the topic of targeting advanced prostate cancer with PARP inhibitors: Who, When and How?
Episode 1 focuses on radium-223 and guest speaker Dr Neal Shore joins the discussion.
Episode 2 focuses on PSMA-targeted radiopharmaceuticals.